GlaxoSmithKline Pharmaceuticals is planning a major comeback in India. The company aims to double its revenue to ₹8,000 crore within the next 4-5 years. This growth will be driven by a strategic shift towards specialty drugs in oncology and liver diseases. Adult vaccination is also a key focus area.

See Full Page